SEK6.76
1.35% yesterday
Stockholm, Aug 05, 05:29 pm CET
ISIN
SE0002478776
Symbol
SEZI

Senzime Stock price

SEK6.76
+1.37 25.42% 1M
+0.84 14.19% 6M
+1.26 22.91% YTD
-1.22 15.29% 1Y
-8.51 55.72% 3Y
-14.35 67.97% 5Y
+1.76 35.20% 10Y
-1.73 20.38% 20Y
Stockholm, Closing price Tue, Aug 05 2025
+0.09 1.35%
ISIN
SE0002478776
Symbol
SEZI

Key metrics

Basic
Market capitalization
SEK1.1b
Enterprise Value
SEK1.1b
Net debt
positive
Cash
SEK62.1m
Shares outstanding
133.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
15.8 | 9.7
EV/Sales
15.2 | 9.4
EV/FCF
negative
P/B
3.6
Financial Health
Equity Ratio
81.1%
Return on Equity
-34.3%
ROCE
-35.2%
ROIC
-39.4%
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
SEK69.9m | SEK113.2m
EBITDA
SEK-94.8m | SEK-65.3m
EBIT
SEK-121.6m | SEK-90.8m
Net Income
SEK-125.5m | SEK-40.8m
Free Cash Flow
SEK-130.6m
Growth (TTM | estimate)
Revenue
72.1% | 93.6%
EBITDA
17.1% | 37.8%
EBIT
10.1% | 30.8%
Net Income
4.4% | 65.7%
Free Cash Flow
-9.3%
Margin (TTM | estimate)
Gross
38.7%
EBITDA
-135.7% | -57.7%
EBIT
-174.1%
Net
-179.6% | -36.0%
Free Cash Flow
-187.0%
More
EPS
SEK-0.9
FCF per Share
SEK-1.0
Short interest
-
Employees
54
Rev per Employee
SEK1.1m
Show more

Is Senzime a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,032 stocks worldwide.

Financial data from Senzime

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
70 70
72% 72%
100%
- Direct Costs 43 43
44% 44%
61%
27 27
149% 149%
39%
- Selling and Administrative Expenses 132 132
4% 4%
188%
- Research and Development Expense 20 20
4% 4%
29%
-95 -95
17% 17%
-136%
- Depreciation and Amortization 27 27
28% 28%
38%
EBIT (Operating Income) EBIT -122 -122
10% 10%
-174%
Net Profit -125 -125
4% 4%
-180%

In millions SEK.

Don't miss a Thing! We will send you all news about Senzime directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Senzime AB engages in the development of enzyme-based biosensor technology for medical and biochemical processes and industries. It manufactures products for automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patient's neuromuscular function perioperatively and in the intensive care medicine setting. The company also distributes bioreactor systems for the pharmaceutical industry. Senzime was founded by Thomas Ambjorn Carlsson in 1999 and is headquartered in Uppsala, Sweden.

Head office Sweden
CEO Mr. Siberg
Employees 54
Founded 1999
Website senzime.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today